Aristides Capital LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Aristides Capital LLC acquired a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,200 shares of the company’s stock, valued at approximately $205,000.

Several other hedge funds also recently made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new stake in Phathom Pharmaceuticals during the fourth quarter worth approximately $74,000. Teacher Retirement System of Texas bought a new stake in shares of Phathom Pharmaceuticals during the 4th quarter worth $90,000. Versor Investments LP bought a new stake in shares of Phathom Pharmaceuticals during the 4th quarter worth $101,000. Virtu Financial LLC acquired a new position in shares of Phathom Pharmaceuticals in the 4th quarter worth $109,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Phathom Pharmaceuticals during the fourth quarter worth $171,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on PHAT. Guggenheim reiterated a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 2nd. Craig Hallum reissued a “buy” rating on shares of Phathom Pharmaceuticals in a research report on Friday, March 7th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Wednesday, April 2nd. Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, The Goldman Sachs Group cut their target price on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Phathom Pharmaceuticals currently has an average rating of “Buy” and an average price target of $22.17.

Insiders Place Their Bets

In other Phathom Pharmaceuticals news, CFO Molly Henderson sold 6,583 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $43,381.97. Following the transaction, the chief financial officer now directly owns 93,546 shares in the company, valued at $616,468.14. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Azmi Nabulsi sold 7,886 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the sale, the chief operating officer now owns 233,390 shares of the company’s stock, valued at approximately $1,538,040.10. This trade represents a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,578 shares of company stock valued at $221,279 in the last three months. Insiders own 24.10% of the company’s stock.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock opened at $4.88 on Monday. Phathom Pharmaceuticals, Inc. has a twelve month low of $4.07 and a twelve month high of $19.71. The firm’s 50 day moving average price is $5.69 and its two-hundred day moving average price is $9.61. The firm has a market cap of $339.83 million, a PE ratio of -0.86 and a beta of 0.35.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.